Estazolam

Benzodiazepine — NERVOUS SYSTEM

Key facts

Estazolam is an ofp drug in the Benzodiazepine class catalogued in DrugCentral. It was first approved by the FDA in 1990. DrugCentral lists 4 molecular targets, including GABRA1|GABRG2|GABRB2, GABRG2|GABRB3|GABRA2 and GABRG2|GABRB3|GABRA3. Recorded indications include Severe Insomnia.

• Approval status: ofp (first approved 1990 by the FDA).
• Drug class: Benzodiazepine.
• Molecular targets: GABRA1|GABRG2|GABRB2, GABRG2|GABRB3|GABRA2, GABRG2|GABRB3|GABRA3 and GABRG2|GABRB3|GABRA5 (4 listed in DrugCentral).
• Indications: Severe Insomnia.
• ATC code: N05CD04 (Benzodiazepine derivatives).
• Molecular formula: C16H11ClN4; molecular weight 294.74 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Severe Insomnia

Contraindications (11)

• Alcohol intoxication
• Breastfeeding (mother)
• Depressive disorder
• Disease of liver
• Kidney disease
• Myasthenia gravis
• Pregnancy, function
• Psychotic disorder
• Severe chronic obstructive pulmonary disease
• Sleep apnea
• Substance abuse

Mechanism & targets

• Established pharmacologic class: Benzodiazepine

Molecular targets (4)

Target	Gene	Action	Activity
GABA-A receptor alpha-1/beta-2/gamma-2	GABRA1|GABRG2|GABRB2	positive allosteric modulator	—
GABA-A receptor alpha-2/beta-3/gamma-2	GABRG2|GABRB3|GABRA2	positive allosteric modulator	—
GABA-A receptor alpha-3/beta-3/gamma-2	GABRG2|GABRB3|GABRA3	positive allosteric modulator	—
GABA-A receptor alpha-5/beta-3/gamma-2	GABRG2|GABRB3|GABRA5	positive allosteric modulator	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1990-12-26	FDA	—	ABBOTT

ATC classification

ATC code	Therapeutic hierarchy
N05CD04	NERVOUS SYSTEM › PSYCHOLEPTICS › HYPNOTICS AND SEDATIVES › Benzodiazepine derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug interaction	119.2
Serotonin syndrome	93.3
Suicide attempt	85.3
Intentional overdose	78.6
Altered state of consciousness	71.5
Disease risk factor	63.1
Inappropriate antidiuretic hormone secretion	58.1
Somnolence	49.2
Delirium	48.6
Rhabdomyolysis	48.3
Drug-disease interaction	46.3
Electrocardiogram QT prolonged	45.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Estazolam is on its molecule page.

• Molecular formula: C₁₆H₁₁ClN₄
• Molecular weight: 294.74 g/mol
• CAS number: 29975-16-4
• InChIKey: CDCHDCWJMGXXRH-UHFFFAOYSA-N
• PubChem CID: 3261

ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Estazolam used for?

DrugCentral lists the following indications for Estazolam: Severe Insomnia.

How does Estazolam work?

Its molecular targets in DrugCentral include GABRA1|GABRG2|GABRB2 (positive allosteric modulator), GABRG2|GABRB3|GABRA2 (positive allosteric modulator), GABRG2|GABRB3|GABRA3 (positive allosteric modulator) and GABRG2|GABRB3|GABRA5 (positive allosteric modulator).

When was Estazolam first approved?

Estazolam was first approved by the FDA in 1990.

What drug class does Estazolam belong to?

Estazolam is in the Benzodiazepine class.

What is the chemical formula of Estazolam?

Estazolam has the molecular formula C16H11ClN4 and a molecular weight of 294.74 g/mol.

Sources

• DrugCentral drug card 1056 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL285674 — compound record and bioactivity
• PubChem CID 3261 — chemical identifiers
• DrugBank DB01215 — drug record
• FDA UNII 36S3EQV54C — substance identity
• DailyMed: FDA labels for Estazolam — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.